ADAM33 (ADAM metallopeptidase domain 33) encodes a membrane-bound metalloprotease with zinc ion binding capability that functions in proteolysis [GO annotations]. The protein exhibits metalloendopeptidase activity and is involved in extracellular matrix remodeling processes. Multiple genetic polymorphisms in ADAM33 have been extensively associated with respiratory diseases, particularly asthma and chr20 obstructive pulmonary disease (COPD). Meta-analyses demonstrate that specific ADAM33 polymorphisms, including T1 (rs2280091), V4 (rs2787094), F+1 (rs511898), and S2 (rs528557), confer increased susceptibility to asthma, with particularly strong associations observed in Asian populations 1 2 3 4. The T1 polymorphism shows robust association with childhood asthma risk in Asians 3, while the S2 and V4 variants are linked to allergic rhinitis susceptibility 5. For COPD, the S1 polymorphism increases disease risk in Asian populations 6, and the F+1 variant shows significant association with COPD susceptibility, particularly among Asians 7. Clinical validation studies in Thai populations confirm the association between ADAM33 S2 polymorphism and asthma 8. These findings suggest ADAM33 variants may serve as biomarkers for early diagnosis and risk prediction of respiratory diseases.